Literatur
- 1
ACC/AHA/ESC .
2006 Guidelines for the management of patients with atrial fibrillation.
Europ Heart J.
2006;
27
1979-2030
- 2
Benjamin E J, Levy D, Vaziri S M. et
al .
Independent risk factor for atrial fibrillation in a
population-based cohort.
JAMA.
1994;
271
840-844
- 3
Benjamin E J, Wolf P A, D’Agostino R B. et al .
Impact of atrial fibrillation on
the risk of death.
Circulation.
1998;
98
946-952
- 4
Lévy S. et al .
Characterisation of different subsets of
atrial fibrillation in general practice in France.
Circulation.
1999;
99
3028-3035
- 5
Lewalter T, Lüderitz B.
Vorhofflimmern – Interventionelle
Differentialtherapie unter besonderer Berücksichtigung
des Lebensalters.
Dtsch Med Wochenschr.
2005;
130
721-725
- 6
Lloyd-Jones D M. et al .
Lifetime risk for development of atrial
fibrillation: the Framingham Heart Study.
Circulation.
2004;
110
1042-1046
- 7
Nieuwlaat R. et al .
Atrial fibrillation management: a prospective
survey in ESC member countries.
Eur Heart J.
2005;
26
2422-2434
- 8
Stellbrink C. et al .
Safety and efficacy of enoxaparin compared
with unfractionated heparin and oral anticoagulants for prevention
of thromboembolic complications in cardioversion of nonvalvular
atrial fibrillation.
Circulation.
2004;
109
997-1003
- 9
Verdecchia P. et al .
Atrial fibrillation in hypertension: predictors
and outcome.
Hypertension.
2003;
41
218-223
Prof. Dr. med. Th. Lewalter
Chefarzt der Medizinischen Klinik II, Innere
Medizin mit den Schwerpunkten Kardiologie und
Internistische Intensivmedizin, St. Vincenz-Krankenhaus, Akademisches
Lehrkrankenhaus der Universität Göttingen
Am
Busdorf 2
33098 Paderborn
